BridgeBio Pharma (FRA:2CL) Payments of Debt: €0.0 Mil (TTM As of Mar. 2026)


FRA:2CL BridgeBio Pharma Inc FRA:2CL
66 GF Score
Price €68.07
GF Value €128.55
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is BridgeBio Pharma Payments of Debt?

BridgeBio Pharma FRA:2CL +0.70% 66 Payments of Debt is €0.0 Mil as of Mar. 2026. GuruFocus rates FRA:2CL with a GF Score™ of 66/100 and a GF Value™ of €128.55 (Possible Value Trap). The stock has 8 warning signs investors should review.

BridgeBio Pharma's Payments of Debt for the three months ended in Mar. 2026 was €0.0 Mil.

BridgeBio Pharma's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was €0.0 Mil.

BridgeBio Pharma Payments of Debt Related Terms

BridgeBio Pharma Payments of Debt Historical Data

* Premium members only.

The historical data trend for BridgeBio Pharma's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma Payments of Debt Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial Premium Member Only -109.85 -19.34 0.00 -452.11 -391.99

BridgeBio Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -424.58 0.00 0.00 0.00 0.00
FRA:2CL
66GF Score
BridgeBio Pharma Inc FRA:2CL
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BridgeBio Pharma Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €0.0 Mil mean?
BridgeBio Pharma (FRA:2CL) has a Payments of Debt of €0.0 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on BridgeBio Pharma and its competitors.
Is BridgeBio Pharma's Payments of Debt too high?
BridgeBio Pharma's current Payments of Debt is €0.0 Mil. Overall, BridgeBio Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Payments of Debt compare to EXEL and IONS?
BridgeBio Pharma's Payments of Debt of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on BridgeBio Pharma and its competitors. BridgeBio Pharma's current Payments of Debt is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €128.55, compared to a current price of €68.07 — trading 47% below its estimated fair value. The current Payments of Debt is €0.0 Mil. BridgeBio Pharma's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Payments of Debt is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €68.07 is trading 47% below its estimated GF Value™ of €128.55. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Payments of Debt: €0.0 Mil
  • GF Value™: €128.55 vs. price of €68.07 (47% below fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
66GF Score

Get the complete analysis for FRA:2CL

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.07
Price
€128.55
GF Value